FDA advisory panel on the safety and efficacy of drug-eluting stents: Summary of findings and recommendations

Journal of Interventional Cardiology

Volumn 20, Issue 6, 2007, Pages 425-446

  Popma, Jeffrey J ^a   Weiner, Bonnie ^b   Cowley, Michael J ^b   Simonton, Charles ^b   McCormick, Dan ^b   Feldman, Ted ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FOOD AND DRUG ADMINISTRATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; THROMBOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36549032753     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00312.x     Document Type: Review

References (85)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994 331 : 496 501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med 1994 331 : 489 495.
3. Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998 339 : 1665 1671.
4. Uchida T, Farb A, Holton A, et al. FDA Summary. http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006 - 4253oph1_17_FDA%20Summary.pdf 2006.
5. Cutlip D, Chauhan M, Baim D, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002 40 : 2082 2089.
6. Moses J. Clinician's perspective on drug-eluting stents: Balancing safety and efficacy. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_10_Moses.pdf 2006.
7. Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: Long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000 35 : 1569 1576.
8. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006 151 : 1260 1264.
9. Walters DL, Harding SA, Walsh CR, et al. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 2002 89 : 491 494.
10. Mishkel G. Prairie "Real World" drug-eluting stent database. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_06_Mishkel.pdf 2006.
11. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 2006 70 : 1026 1029.
12. Sousa J, Costa M, Sousa A, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003 107 : 381 383.
13. Morice M, Serruys P, Sousa J, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 346 : 1773 1780.
14. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 349 : 1315 1323.
15. Grube E, Silber S, Hauptmann K, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003 107 : 38 42.
16. Colombo A. TAXUS-II results. 52nd Annual ACC Scientific Sessions, Chicago, March 30, 2003.
17. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 350 : 221 231.
18. Camenzind E. Safety of drug-eluting stents. World Congress of Cardiology, Barcelona, Spain, September 2-6, 2006.
19. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006 27 : 2784 2814.
20. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006 113 : 2803 2809.
21. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005 293 : 2126 2130.
22. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005 45 : 2088 2092.
23. Lagerqvist B, Wallentin L. Long-term outcome of DES vs. BMS implanted in Sweden 2003-2004. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_07_Wallentin.pdf 2006.
24. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987 316 : 701 706.
25. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005 294 : 1215 1223.
26. Ong A, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005 45 : 947 953.
27. Ong A, McFadden E, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005 45 : 2088 2092.
28. Cutlip D. Impact of stent thrombosis on outcomes of death and MI after drug-eluting stenting. Importance of standard definitions and analytical methods. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_03_Cutlip.pdf 2006.
29. Waksman R. DES thrombosis results from contemporary registries at the Washington Hospital Center. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_08_Waksman.pdf 2006.
30. Fiorentino R. Stent thrombosis: The implications of broader DES use. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_18_Fiorention-FDA. pdf 2006.
31. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006 113 : 1108 1113.
32. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005 293 : 2126 2130.
33. Cohen S. "Real World": Use of the CYPHER sirolimus-eluting stent. Data from randomized controlled trial and registries. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_14_Cohen-Cordis. pdf 2006.
34. Virmani R, Gold H, FInn A, et al. The vascular pathology of drug-eluting stent: Delayed healing and late thrombotic risk. http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006 - 4253oph1_01_Herman%20Gold.pdf 2006.
35. Finn A, Kolodgie F, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005 112 : 270 278.
36. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002 106 : 2649 2651.
37. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006 48 : 193 202.
38. Michelson M. Late stent thrombosis after DES: Role of platelet function testing. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_02_Michelson.pdf 2006.
39. Hillman R. What is the right dose, timing, and duration of clopidogrel therapy when used with drug-eluting stents. http://www.fda.gov/ohrms/dockets/ac/ 06/slides/2006 - 4253oph2_16_Hillman.pdf 2006.
40. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003 59 : 295 302.
41. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. J Am Coll Cardiol 2005 45 : 1753 1756.
42. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 2005 46 : 1827 1832.
43. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006 113 : E166 E286.
44. Abizaid A. FDA Panel on DES. http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006 - 4253oph2_01_Abizaidl.pdf 2006.
45. Serruys P, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002 106 : 798 803.
46. Stone G. Perspectives on drug-eluting stent safety and efficacy with regulatory recommendations. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_04_Stone.pdf 2006.
47. Rogers C. Drug-eluting safety profile stent thrombosis. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_13_Rogers-Cordis. pdf 2006.
48. Baim D. FDA panel on drug-eluting stent safety. Boston Scientific presentation: Part 1. On-label use of the TAXUS drug-eluting stent system. 2006.
49. Kuntz RE. Medtronic Vascular: Endeavor safety analysis. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_17_Kuntz.pdf 2006.
50. Fajadet J, Wijns W, Laarman G, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006 114 : 798 806.
51. Sudhir K. Abbott Vascular drug-eluting stent program. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_18_Sudhiri.pdf 2006.
52. Finn A, Nakazawa G, Joner M, et al. Everolimus-eluting stents: Beyond targeting restenosis. Eurointervention 2006 2 : 277 279.
53. Statement F. Update to the FDA statement on coronary drug-eluting stents. http://www.fda.gov/cdrh/news/010407.html 2006.
54. Kaul S, Diamond G. Drug-eluting stents: Balancing risks and benefits. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_09_Kaul.pdf 2006.
55. Williams DO. Comparisons of drug-eluting to bare metal stents: Findings from the NHLBI-Dynamic and the DEScover registries. http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006 - 4253oph2_05_Williams.pdf 2006.
56. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006 355 : 1093 1104.
57. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs. abciximab and bare metal stent for acute myocardial infarction: A randomized trial. JAMA 2005 293 : 2109 2117.
58. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005 112 : 2175 2183.
59. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial. JAMA 2004 292 : 2727 2734.
60. Moses JW, Nikolsky E, Mehran R, et al. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: The SIRIUS 2.25 trial. Am J Cardiol 2006 98 : 1455 1460.
61. Hirohata A, Morino Y, Ako J, et al. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial). Am J Cardiol 2006 98 : 1464 1467.
62. Holmes DR, Jr., Teirstein P, Satler L, et al. Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare metal stents: The SISR randomized trial. JAMA 2006 295 : 1264 1273.
63. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary stenting of totally occluded native coronary arteries II (PRISON II): A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006 114 : 921 928.
64. Baim DS. Boston Scientific presentation: Part II. Real-world use of the TAXUS drug-eluting stent. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_15_Baim-Boston.pdf 2006.
65. Williams DO, Abbott JD, Kip KE. Outcomes of 6,906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover registry. Circulation 2006 114 : 2154 2162.
66. Daemen J, Wenaweser P, Tsuchida K, et al. Late coronary stent thrombosis of DES in routine clinical practice - data from a larger two-institutional cohort study. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_08_%20Serruys.pdf 2006.
67. Mehran R. A prospective "all comers" single-arm study in complex patients: The MATRIX registry. http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006 - 4253oph2_02_Mehran.pdf 2006.
68. Henry T. Impact of DES in STEMI: The Minneapolis Heart Institute Level 1 MI Program. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_14_Henry.pdf 2006.
69. Smith P. Relative merits and clinical selection of CABG, bare metal stents, and drug-eluting stents in practice and in evolution. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_11_Smith.pdf 2006.
70. State NY. New York State CABG versus PCI. N Engl J Med 2005 352 : 2174.
71. England NN. Northern New England Database. Circulation 2005 2005 (Suppl. 1 I371 I376.
72. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006 82 : 1420 1428.
73. Guyton R. History of evidence-based coronary revascularization - can we identify our mistakes and not repeat them? http://www.fda.gov/ohrms/dockets/ac/ 06/slides/2006 - 4253oph2_12_Guyton.pdf 2006.
74. Gersh BJ, Frye RL. Methods of coronary revascularization - Things may not be as they seem. N Engl J Med 2005 352 : 2235 2237.
75. van Es G-A. Adjudication of events for FDA Panel. http://www.fda.gov/ ohrms/dockets/ac/06/slides/2006 - 4253oph1_12_Van%20Es.pdf 2006.
76. Ong AT, Serruys PW, Mohr FW, et al. The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006 151 : 1194 204.
77. Colombo A. Incidence and predictors of drug-eluting stent thrombosis during and following discontinuation of thienopyridine treatment. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph1_06_Columbo.pdf 2006.
78. Magid D, Brindis R, Go A. Longitudinal outcomes following drug-eluting stent implantation. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006- 4253oph2_04_Magid.pdf 2006.
79. Pfisterer M, Brunner-La RHP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare metal stents. J Am Coll Cardiol 2006 48 : 2584 2591.
80. Eisenstein E, Andstrom K, Kong D, et al. Clopiodogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007 297 : online.
81. Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001 358 : 527 533.
82. Steinhubl S, Berger P, Mann J, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002 288 : 2411 2420.
83. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 : 1706 1717.
84. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 2006 354 : 1744 1746.
85. Mauri L. Planned combined safety analysis for stents utilizing biolimus A9 and biodegradable polymer. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006 - 4253oph2_19_Mauri.pdf 2006.